Logo

American Heart Association

  2
  0


Final ID: MDP790

Performance of a Protein Language Model for Variant Annotation in Cardiac Disease

Abstract Body (Do not enter title and authors here): Introduction: Genetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as Variants of Unknown Significance (VUS), limiting the utility of testing.
Recently, the DeepMind group (Google, USA) developed AlphaMissense, a unique Artificial Intelligence (AI) based model, based on language model principles for the prediction of missense variant pathogenicity.
Objective: To report on the performance of AlphaMissense, accessed by VarCardio, an open web-based variant annotation engine, in a real-world cardiovascular genetics center.
Methods: All genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared to the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype-phenotype concordance were examined for all variants in the study.
Results: We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either VUS or non-classified. Using VarCard.io, 198 VUSs (86.1%, CI 80.9-90.3%) were reclassified to either Likely Pathgenic (LP) or Likely benign (LB). The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% vs 34.8%, p<0.001).
Genotype-Phenotype concordance was highly aligned using VarCard.io predictions, at 95.9% (CI 92.8-97.9%) concordance rate. For 109 variants classified as Pathogenic, LP, Benign or LB by ClinVar, concordance with VarCard.io was high (90.5%).
Conclusion: AlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine's notable performance in assessing variants that are classified as VUS in ClinVar, demonstrates its potential to enhance cardiac genetic testing.
  • Hochstadt, Aviram  ( NYU langone health , New York , New York , United States )
  • Martin, Jacob  ( NYU langone health , New York , New York , United States )
  • Park, David  ( NYU langone health , New York , New York , United States )
  • Spinelli, Michael  ( NYU langone health , New York , New York , United States )
  • Chinitz, Larry  ( NYU langone health , New York , New York , United States )
  • Jankelson, Lior  ( NYU langone health , New York , New York , United States )
  • Barbahya, Chirag  ( NYU langone health , New York , New York , United States )
  • Aizer, Anthony  ( NYU langone health , New York , New York , United States )
  • Bernstein, Scott  ( NYU langone health , New York , New York , United States )
  • Cerrone, Marina  ( NYU langone health , New York , New York , United States )
  • Garber, Leonid  ( NYU langone health , New York , New York , United States )
  • Holmes, Douglas  ( NYU langone health , New York , New York , United States )
  • Knotts, Robert  ( NYU langone health , New York , New York , United States )
  • Kushnir, Alex  ( NYU langone health , New York , New York , United States )
  • Author Disclosures:
    Aviram Hochstadt: DO NOT have relevant financial relationships | Jacob Martin: DO NOT have relevant financial relationships | David Park: No Answer | Michael Spinelli: No Answer | Larry Chinitz: DO have relevant financial relationships ; Consultant:Medtronic:Active (exists now) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:Biosense Webster:Active (exists now) ; Consultant:Abbott:Active (exists now) | Lior Jankelson: No Answer | Chirag Barbahya: No Answer | Anthony Aizer: DO have relevant financial relationships ; Consultant:Biotronik:Past (completed) ; Consultant:Abbott:Past (completed) ; Consultant:Medtronic:Past (completed) ; Consultant:Biosense Webster:Past (completed) ; Consultant:Boston Scientific:Past (completed) | Scott Bernstein: No Answer | Marina Cerrone: DO have relevant financial relationships ; Speaker:Medtronic:Past (completed) ; Consultant:arvada tx:Active (exists now) ; Consultant:Guidepoint:Active (exists now) ; Speaker:Abbott:Past (completed) | Leonid Garber: No Answer | Douglas Holmes: No Answer | Robert Knotts: No Answer | Alex Kushnir: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Genomics and Informatics

Sunday, 11/17/2024 , 09:30AM - 10:35AM

Moderated Digital Poster Session

More abstracts on this topic:
Age-stratified Monogenic and Polygenic Contributions for Atrial Fibrillation in the All of Us Research Program

Chen Zhanlin, Gordon Adam, Webster Gregory

Can the reduction of mutant endothelial cells hold promise for treating brain arteriovenous malformation?

Shabani Nabikandi Zahra, Prado Leandro, Shaligram Sonali, Zhang Rui, Zhu Wan, Liang Rich, Yadav Alka, Wang Calvin, Su Hua

More abstracts from these authors:
Catheter Ablation Alone Versus Catheter Ablation With Combined Percutaneous Left Atrial Appendage Closure For Atrial Fibrillation: A Systematic Review and Meta-analysis

Junarta Joey, Aizer Anthony, Siddiqui Muhammad, Abaza Ehab, Zhang Peter, Roshandel Aarash, Barbhaiya Chirag, Jankelson Lior, Park David, Chinitz Larry

Individualized Ablation Strategies Optimize First Pass Isolation and Minimize Pulmonary Vein Reconnection During Atrial Fibrillation Ablation

Junarta Joey, Bernstein Scott, Park David, Chinitz Larry, Aizer Anthony, Qiu Jessica, Cheng Austin, Barbhaiya Chirag, Jankelson Lior, Holmes Douglas, Kushnir Alexander, Knotts Robert, Yang Felix

You have to be authorized to contact abstract author. Please, Login
Not Available